PEP-CMV
Phase 2Biologic
PEP-CMV is one of 40 biologic programs targeting Malignant Glioma. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
34 competitors in Malignant Glioma
#DrugCompanyPhaseTrials
1Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Ziagen
GSKApproved
Afinitor
NovartisApproved
Plaquenil
Jazz PharmaceuticalsApproved
Levulan
Sun Pharmaceutical Industries, Inc.Approved
Lynparza
AstraZenecaApproved
Norvir
AbbVieApproved
Tafinlar
NovartisApproved
Minocin
TTriax
Approved
Vermox
WWim Janssens
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PEP-CMV. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Florida